<DOC>
	<DOCNO>NCT01908322</DOCNO>
	<brief_summary>The study aim investigate patient characteristic intermediate stage hepatocellular carcinoma patient treat Nexavar distribution different treatment group well determine efficacy safety parameter .</brief_summary>
	<brief_title>Investigating Patient Characteristics Intermediate Stage Hepatocellular Carcinoma Patients Treated With Nexavar Their Distribution Different Treatment Groups Well Determining Effectiveness Safety</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<criteria>Patients diagnosis unresectable intermediate stage hepatocellular carcinoma ( BCLCB ) decision take investigator prescribe Nexavar ( BCLC intermediate stage ( BCLCB ) consist ChildPugh A B patient large/multifocal HCC cancer relate symptom , macrovascular invasion extrahepatic spread ) . Prior target therapy hepatocellular carcinoma .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Hepatocellular carcinoma</keyword>
	<keyword>Intermediate stage</keyword>
	<keyword>Observational study</keyword>
</DOC>